



Kilitch Drugs (India) Ltd.

August 13, 2019

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: Outcome of Board Meeting held on August 13, 2019

Dear Sir/Madam,

In continuation to our letter dated August 6, 2019, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 13th August, 2019, have considered & approved the following.

1. Un-audited financial results of the company for the quarter ended June 30, 2019.
2. The Board also noted that the Sudan was facing serious political instability for quite some time. Since last 3 quarters, the Company was not able to source any sales from Sudan which is reflecting in June quarter's financial results.
3. To keep Books of Accounts of the Company at its corporate office at 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai-400088, as a place other than the registered office of the Company.


In this connection please find enclosed the copy of Un-audited Standalone financial Results of the Company for the quarter ended 30th June, 2019 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".

The meeting commenced at 11:00 A.M. and concluded at 5.10 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For **Kilitch Drugs (India) Limited**


Mukund Mehta

Manging Director

DIN: 00147876

Encl: as above



Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. • Tel.: +91-22-6121 4100 • Fax : +91-22-6703 1658

Registered Office & Manufacturing unit : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra.

• CIN: L24239MH1992PLC066718 • Tel.: +91-22-2767 0322 / 2768 0913 • Fax : +91-22-2768 0912 • E-mail : info@kilitch.com • Website : www.kilitch.com

A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

224, Champaklal Industrial Estate
Sion-Koliwada Road, Sion (East),
Mumbai - 400 022.
Tel : 2402 4909 / 8739
Fax : 2407 1138
E-mail : amghelaniandco@gmail.com

AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

To,
The Board of Directors
Kilitch Drugs (India) Limited

LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30TH JUNE, 2019

1. We have reviewed the accompanying statement of unaudited standalone financial results of KILITCH DRUGS (INDIA) LIMITED (the 'Company') for the quarter ended 30th June, 2019 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specifies under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company

Chartered Accountants

FRN: 103173W



Chintan Ghelani

Partner

Membership No.: 104391

ICAI UDIN: 19104391AAAABY6899

Place : Mumbai

Dated: 13th August, 2019



Encl: Unaudited financial results for the quarter ended 30th June, 2019

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. in Lakhs)

Sr. No.	Particulars	STANDALONE			
		Three Months Ended		Year Ended	
		30/06/2019	31/03/2019	30/06/2018	31/03/2019
		Unaudited	Audited	Unaudited	Audited
1	Income from operations				
	Net Sales/ Income from operations	1,198.27	2,239.71	2,797.34	9,641.76
	Other Income	175.48	(6.38)	236.77	451.82
	Total Income from Operations	1,373.75	2,233.33	3,034.11	10,093.58
2	Expenses				
	(a) Cost of Materials Consumed	883.08	1,106.41	1,765.53	5,316.22
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(105.07)	75.34	(55.31)	(17.70)
	(c) Employee Benefit Expenses	132.58	139.93	136.37	522.89
	(d) Finance Cost	15.10	37.91	-	37.91
	(e) Depreciation and Amortisation Expenses	22.48	34.01	26.01	120.38
	(f) Export Product Registration/Commission	124.88	164.65	64.06	683.93
	(g) Other Expenses	210.99	321.62	563.35	1,477.48
	Total Expenses	1,284.04	1,879.87	2,500.01	8,141.11
3	Profit / (Loss) before Exceptional items (1-2)	89.71	353.46	534.10	1,952.47
4	Exceptional Items	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	89.71	353.46	534.10	1,952.47
6	Tax Expenses:				
	Current Tax	4.65	90.47	59.12	424.08
	Deferred Tax	20.62	(2.34)	58.07	51.66
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	64.44	265.33	416.91	1,476.73
8	Other Comprehensive Income (after tax)	(37.21)	61.18	(29.59)	(105.69)
9	Total Comprehensive Income (after taxes) (7+8)	27.23	326.51	387.32	1,371.04
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,541.75	1,535.52	1,373.18	1,535.52
11	Other Equity				13,572.84
12	Earnings per share				
	(a) Basic (not annualised)	0.42	1.68	3.04	10.06
	(b) Diluted (not annualised)	0.42	1.68	2.72	10.06




Notes:

1. The above unaudited results as reviewed by the Audit Committee have been taken on record by the Board of Directors at their meeting held on 13th August, 2019.
2. The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The company has issued 62,239 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th June, 2019.
4. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
5. The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the company's accounting for recognition of revenue.
6. The figures for the quarter ended 31st March, 2019 are the balancing figures between the audited figures in respect of the full financial year and the year-to-date figures up to the third quarter of the said financial year.
7. The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai

Date: 13th August, 2019

For and on behalf of the Board of Directors


Mukund P. Mehta
Managing Director

